Adoptive Immunotherapy Of Cancer Using Autologous Lymphocytes
CANCER MANAGEMENT IN MAN: CHEMOTHERAPY, BIOLOGICAL THERAPY, HYPERTHERMIA AND SUPPORTING MEASURES(2011)
摘要
Adoptive immunotherapy (AIT) of cancer using lymphocytes is a highly promising modality for eradicating cancer. The AIT strategy
is less dependently of cancer-associated immune dysfunction, which exists in tumor-bearing host. The cloning of interleukin-2
(IL-2) has facilitated to manipulate and to propagate effector cells. Lymphokine-activated killer (LAK) cells and tumor-infiltrating
lymphocytes (TILs) were introduced into clinical trials for cancer treatment and demonstrated, to some extents, objective
tumor responses. Identification of tumor antigens and understanding of antigen presentation and recognition machinery has
permitted to stimulate HLA-restricted antigen-specific lymphocytes with dendritic cells (DCs) and tumor antigens, including
peptide, tumor lysate, tumor fusion, and tumor RNA. HLA-un-restricted effector cells, including NKT cells and γδT cells, have
also been promising to investigate. It is the most important to define and establish a suitable culture system that can permit
adequate expansion of effector lymphocytes with sufficient activities that can persist in vivo. It must also be of importance
to conduct scientific clinical trials for establishing effective AIT applications. I believe, the time is coming soon when
the AIT can provide clinical benefits for patients with advanced cancer in the world.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要